BioLine Rx (BLRX) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

BioLine Rx Ltd (BLRX) Prix de l'Action, Cotation, Actualités et Historique

BLRXNASDAQ

Trade with Public

Trade with Public

$2.21

0.0050.23%

Dern. MÀJ: Oct 8, 9:04 AM

$2.26

0.05622.55%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$2.31

Clôture

$2.21

Volume / Moy.

18.37K / 19.41K

Fourchette Journalière

$2.17 - $2.31

Plage 52 Sem.

2.15 - 4.56

Capitalisation Boursière

$11.26M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

35

Intérêt à Découvert

2.93%

Jours pour Couvrir

6.05

Actualités Récentes de BioLine RX Ltd

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

Vandana Singh

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.

Avi Kapoor

3 Stocks Getting Rare Double Upgrades From Analysts

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts’ expectations. However, that can become an opportunity for nimble investors with some cash on

MarketBeat

Dow Edges Higher; Dell Shares Fall After Q1 Results

Avi Kapoor

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

Vandana Singh

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-10.80M

Flux de Trésorerie d'Investissement (TTM)

12.39M

Flux de Trésorerie de Financement (TTM)

-4.49M

Flux de Trésorerie Libre (TTM)

-10.83M

Dépenses en Capital (TTM)

-

Variation Nette de la Trésorerie (TTM)

-2.90M

Évaluation et prévisions des analystes

4.0

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$6.63M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

6.99

Ratio P/B (TTM)

0.80

Rendement des Bénéfices % (TTM)

0.00%

Rendement des Bénéfices % (FWD)

-56.92%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$2.77

Dette Entreprise

Dette Totale

$6.70M

Dette à Long Terme

$2.22M

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-$374.00K

Trésorerie Totale

$4.63M

Dette sur Capitaux Propres

0.58

Émission de Dette (TTM)

-$374.00K

Remboursement de la Dette (TTM)

-$4.87M